A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 7, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG

SI-B001

Administration by intravenous infusion

DRUG

SI-B003

Administration by intravenous infusion

Trial Locations (1)

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY